Table 3.

Baseline characteristics of patients with PD-L1 positive and negative expression on tumor-associated macrophages.

	PD-L1 positive (n = 21)	PD-L1 negative (n = 25)
Median Age (years)	58.9	61.0	p = 0.721
Gender
Male	11 (52.4%)	16 (64.0%)
Female	10 (47.6%)	9 (36.0%)	p = 0.550
T stage
T1 a-T1b	1 (4.8%)	2 (8.0%)	p = 0.673
T2 a	1 (4.8%)	2 (8.0%)
T2b	19 (90.4%)	21 (84%)
Grade
1–2	4 (19.1%)	7 (28.0%)	p = 0.514
3	17 (80.9%)	18 (72.0%)
Histologic Subtypes
Undifferentiated Plemorphic Sarcoma	14 (66.7%)	18 (72.0%)	p = 0.755
Liposarcoma	5 (23.8%)	3 (12.0%)
Leimyosarcoma	2 (9.5%)	1 (4.0%)
Other	0 (0%)	3 (12.0%)
Tumor Location
Upper Extremity	1 (4.8%)	2 (8.0%)	p = 0.429
Lower Extremity	19 (90.4%)	20 (80%)
Abdomen/Pelvis	1 (4.8%)	3 (12.0%)
Post-operative Chemotherapy
Yes	4 (19.1%)	3 (12.0%)	p = 0.880
No	17 (80.9%)	22 (88.0%)
Days from Completing XRT to surgery
Median (range)	28 (13–42)	28 (18–54)	p = 0.373